PHARMACIA's ZINECARD FULL APPROVAL DEPENDS ON PHASE IV BREAST CANCER STUDY; CARDIOPROTECTOR MUST SHOW DELAYED PROGRESSION OR SURVIVAL BENEFIT
Executive Summary
"Full approval" by FDA of Pharmacia's Zinecard will depend on results of a Phase IV long-term breast cancer study following dexrazoxane's accelerated approval May 26 for cardioprotection from doxorubicin toxicity in breast cancer patients.